Bin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bin Chen has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Richard Howley
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy Saint Joseph's University Philadelphia Pennsylvania USA
7 shared publicationsMatthew Mansi
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy Saint Joseph's University Philadelphia Pennsylvania USA
6 shared publicationsPratheeba Palasuberniam
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA
6 shared publicationsKenneth A. Myers
Department of Biology, College of Arts and Sciences Saint Joseph's University Philadelphia Pennsylvania USA
5 shared publicationsSharayu Chandratre
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy Saint Joseph's University Philadelphia Pennsylvania USA
5 shared publicationsDaniel Kraus
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA
4 shared publications
Latest Publications
- 16 September 2026
- Published by Wiley in Photochemistry and Photobiology
Effects of ABCG2 knockdown on therapeutic enhancement of 5‐aminolevulinic acid with lapatinib
5‐Aminolevulinic acid (ALA) is administered as a prodrug for tumor fluorescence detection and photodynamic therapy (PDT) after being converted endogenously to the active drug protoporphyrin IX (PpIX). As a substrate of the ABCG2 transporter, PpIX is subject to outward transport in cells with ABCG2 expression, resulting in reduced PpIX fluorescence and PDT effect. Due to the lack of approved ABCG2 inhibitors, lapatinib (Lap), a kinase inhibitor approved for cancer treatment, has been repurposed as an ABCG2 inhibitor for the enhancement of ALA. To provide evidence that Lap enhances ALA by inhibiting ABCG2, we knocked down ABCG2 in four tumor cell lines and evaluated the effects of Lap on enhancing ALA‐PpIX fluorescence and PDT in the wild‐type and ABCG2‐knockdown cell lines. ABCG2 knockdown enhanced ALA‐PpIX fluorescence and PDT response, underscoring the importance of ABCG2 in regulating intracellular PpIX accumulation. However, compared with the corresponding wild‐type cell lines, Lap induced less enhancement of PpIX fluorescence and PDT in ABCG2‐knockdown cell lines, particularly at high concentrations and in cell lines with low ABCG2 activities. By downregulating ABCG2 in tumor cells, we showed that Lap‐induced ALA enhancement was reduced, demonstrating that Lap enhances ALA by blocking ABCG2‐mediated PpIX efflux.
- 16 September 2026
- Published by Wiley in Photochemistry and Photobiology
Effects of ABCG2 knockdown on therapeutic enhancement of 5‐aminolevulinic acid with lapatinib
5‐Aminolevulinic acid (ALA) is administered as a prodrug for tumor fluorescence detection and photodynamic therapy (PDT) after being converted endogenously to the active drug protoporphyrin IX (PpIX). As a substrate of the ABCG2 transporter, PpIX is subject to outward transport in cells with ABCG2 expression, resulting in reduced PpIX fluorescence and PDT effect. Due to the lack of approved ABCG2 inhibitors, lapatinib (Lap), a kinase inhibitor approved for cancer treatment, has been repurposed as an ABCG2 inhibitor for the enhancement of ALA. To provide evidence that Lap enhances ALA by inhibiting ABCG2, we knocked down ABCG2 in four tumor cell lines and evaluated the effects of Lap on enhancing ALA‐PpIX fluorescence and PDT in the wild‐type and ABCG2‐knockdown cell lines. ABCG2 knockdown enhanced ALA‐PpIX fluorescence and PDT response, underscoring the importance of ABCG2 in regulating intracellular PpIX accumulation. However, compared with the corresponding wild‐type cell lines, Lap induced less enhancement of PpIX fluorescence and PDT in ABCG2‐knockdown cell lines, particularly at high concentrations and in cell lines with low ABCG2 activities. By downregulating ABCG2 in tumor cells, we showed that Lap‐induced ALA enhancement was reduced, demonstrating that Lap enhances ALA by blocking ABCG2‐mediated PpIX efflux.
- 17 November 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 102 (3) , 666-675
Combination of iron chelator deferoxamine and ABCG2 transporter inhibitor lapatinib for therapeutic enhancement of 5‐aminolevulinic acid
The use of 5‐aminolevulinic acid (ALA)‐induced protoporphyrin IX (PpIX) for tumor fluorescence imaging and photodynamic therapy (PDT) may be limited by intrinsic PpIX‐reducing mechanisms including PpIX bioconversion and efflux transport. The effectiveness of targeting these PpIX‐reducing mechanisms was evaluated in glioblastoma cell lines. Although either inhibiting PpIX bioconversion by an iron chelator deferoxamine (DFO) or suppressing PpIX efflux by an ABCG2 transporter inhibitor lapatinib (Lap) significantly increased ALA‐PpIX and PDT effect in the A172 cell line with weak ABCG2 activity, DFO in combination with Lap led to significantly greater enhancement effects. However, DFO did not significantly enhance ALA in H4, U‐87, and U‐118 cell lines with robust ABCG2 activities, whereas Lap showed effective enhancement effects. The combination of DFO and Lap enhanced ALA‐induced PpIX and PDT in these three cell lines. Not just increasing ALA‐PpIX levels, Lap enhanced PpIX localization in the mitochondria and promoted mitochondria‐mediated apoptosis after PDT in the H4 cell line with strong ABCG2 activities. Our results demonstrate that blocking ABCG2‐mediated PpIX efflux is critical for the enhancement of ALA and, in tumor cells with ABCG2 activities, inhibiting PpIX bioconversion by DFO needs to be combined with PpIX efflux suppression for effective enhancement of ALA.
- 17 November 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 102 (3) , 666-675
Combination of iron chelator deferoxamine and ABCG2 transporter inhibitor lapatinib for therapeutic enhancement of 5‐aminolevulinic acid
The use of 5‐aminolevulinic acid (ALA)‐induced protoporphyrin IX (PpIX) for tumor fluorescence imaging and photodynamic therapy (PDT) may be limited by intrinsic PpIX‐reducing mechanisms including PpIX bioconversion and efflux transport. The effectiveness of targeting these PpIX‐reducing mechanisms was evaluated in glioblastoma cell lines. Although either inhibiting PpIX bioconversion by an iron chelator deferoxamine (DFO) or suppressing PpIX efflux by an ABCG2 transporter inhibitor lapatinib (Lap) significantly increased ALA‐PpIX and PDT effect in the A172 cell line with weak ABCG2 activity, DFO in combination with Lap led to significantly greater enhancement effects. However, DFO did not significantly enhance ALA in H4, U‐87, and U‐118 cell lines with robust ABCG2 activities, whereas Lap showed effective enhancement effects. The combination of DFO and Lap enhanced ALA‐induced PpIX and PDT in these three cell lines. Not just increasing ALA‐PpIX levels, Lap enhanced PpIX localization in the mitochondria and promoted mitochondria‐mediated apoptosis after PDT in the H4 cell line with strong ABCG2 activities. Our results demonstrate that blocking ABCG2‐mediated PpIX efflux is critical for the enhancement of ALA and, in tumor cells with ABCG2 activities, inhibiting PpIX bioconversion by DFO needs to be combined with PpIX efflux suppression for effective enhancement of ALA.
- Open Access
- 8 October 2025
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 30 (S3) , 1-29
Emerging uses of 5-aminolevulinic-acid-induced protoporphyrin IX in medicine: a review of multifaceted, ubiquitous, molecular diagnostic, therapeutic, and theranostic opportunities
Significance5-Aminolevulinic acid (5-ALA) is a medical pro-drug used to induce the intracellular production of protoporphyrin IX (PpIX) via the heme synthesis pathway. Discoveries in mechanisms and developments in novel applications still continue with this uniquely endogenous intracellular optical system.AimUnderstanding and exploiting the growing uses can be advanced through a survey of knowledge on the mechanisms and biokinetics of 5-ALA administration, partitioning, PpIX production, localization changes, clearance mechanisms, biological interactions, and methods for unique activation methods in both diagnostic and therapeutic applications.ApproachThe current medical uses of PpIX are reviewed, separating into therapeutic and diagnostic areas, and the expansion and lateral growth areas are outlined.ResultsInitially approved for photodynamic therapy of skin lesions, fluorescence diagnostic indications later developed to guide surgical resection in bladder cancer and glioma. Today, the 5-ALA-PpIX system’s spatial-temporal complexity in photophysics and pharmacokinetics continues to lead to more uses, such as photodynamic priming to alter tissue, fast intracellular tissue oxygen sensing, infection, and burn imaging and therapy.ConclusionsThe 5-ALA-PpIX system has broad potential partly because of the ubiquity of the heme synthesis across many cell/tissue types, combined with natural selectivity, unique pharmacokinetics, bright fluorescence, and sufficiently strong singlet oxygen production.
- 8 October 2025
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 30 (S3) , 1-29
Open AccessEmerging uses of 5-aminolevulinic-acid-induced protoporphyrin IX in medicine: a review of multifaceted, ubiquitous, molecular diagnostic, therapeutic, and theranostic opportunities
Significance5-Aminolevulinic acid (5-ALA) is a medical pro-drug used to induce the intracellular production of protoporphyrin IX (PpIX) via the heme synthesis pathway. Discoveries in mechanisms and developments in novel applications still continue with this uniquely endogenous intracellular optical system.AimUnderstanding and exploiting the growing uses can be advanced through a survey of knowledge on the mechanisms and biokinetics of 5-ALA administration, partitioning, PpIX production, localization changes, clearance mechanisms, biological interactions, and methods for unique activation methods in both diagnostic and therapeutic applications.ApproachThe current medical uses of PpIX are reviewed, separating into therapeutic and diagnostic areas, and the expansion and lateral growth areas are outlined.ResultsInitially approved for photodynamic therapy of skin lesions, fluorescence diagnostic indications later developed to guide surgical resection in bladder cancer and glioma. Today, the 5-ALA-PpIX system’s spatial-temporal complexity in photophysics and pharmacokinetics continues to lead to more uses, such as photodynamic priming to alter tissue, fast intracellular tissue oxygen sensing, infection, and burn imaging and therapy.ConclusionsThe 5-ALA-PpIX system has broad potential partly because of the ubiquity of the heme synthesis across many cell/tissue types, combined with natural selectivity, unique pharmacokinetics, bright fluorescence, and sufficiently strong singlet oxygen production.
- 3 February 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 101 (6) , 1529-1540
A novel acquired resistance mechanism to 5‐aminolevulinic acid‐mediated photodynamic therapy with ABCG2 inhibition
We report the occurrence of acquired tumor cell resistance to 5‐aminolevulinic acid (ALA)‐mediated photodynamic therapy (PDT) in combination with ABCG2 inhibition. ALA‐PDT in combination with either an ABCG2 tool inhibitor Ko143 or a repurposed clinically‐relevant ABCG2 inhibitor lapatinib was highly effective in eradicating the H4 human glioma cells, resulting in minimal cell survival after treatment. However, after seven rounds of repeated treatments with light dose escalation, the resultant tumor cells became resistant to the combination therapy. The resistant sublines and the parental cell line showed similar ABCG2 activities and protein levels, indicating that it was not ABCG2 that caused the resistance. They also exhibited similar responses to PpIX‐PDT and mTOR inhibitor AZD2014, suggesting that alterations in PDT sensitivity and mTOR pathway had little contribution to the development of resistance phenotype. By determining the intracellular and extracellular PpIX levels, the activities and protein levels of heme biosynthesis enzymes, we found that porphobilinogen deaminase (PBGD) activity and protein level were significantly reduced in the resistant sublines, causing resistance to PDT by substantially reducing PpIX biosynthesis. A novel acquired resistance mechanism to ALA‐PDT with ABCG2 inhibition has been uncovered.
- 3 February 2025
- Published by Wiley in Photochemistry and Photobiology
- Vol. 101 (6) , 1529-1540
A novel acquired resistance mechanism to 5‐aminolevulinic acid‐mediated photodynamic therapy with ABCG2 inhibition
We report the occurrence of acquired tumor cell resistance to 5‐aminolevulinic acid (ALA)‐mediated photodynamic therapy (PDT) in combination with ABCG2 inhibition. ALA‐PDT in combination with either an ABCG2 tool inhibitor Ko143 or a repurposed clinically‐relevant ABCG2 inhibitor lapatinib was highly effective in eradicating the H4 human glioma cells, resulting in minimal cell survival after treatment. However, after seven rounds of repeated treatments with light dose escalation, the resultant tumor cells became resistant to the combination therapy. The resistant sublines and the parental cell line showed similar ABCG2 activities and protein levels, indicating that it was not ABCG2 that caused the resistance. They also exhibited similar responses to PpIX‐PDT and mTOR inhibitor AZD2014, suggesting that alterations in PDT sensitivity and mTOR pathway had little contribution to the development of resistance phenotype. By determining the intracellular and extracellular PpIX levels, the activities and protein levels of heme biosynthesis enzymes, we found that porphobilinogen deaminase (PBGD) activity and protein level were significantly reduced in the resistant sublines, causing resistance to PDT by substantially reducing PpIX biosynthesis. A novel acquired resistance mechanism to ALA‐PDT with ABCG2 inhibition has been uncovered.
- Open Access
- 27 August 2024
- Published by Wiley in Photochemistry and Photobiology
- Vol. 100 (6) , 1603-1621
PpIX‐enabled fluorescence‐based detection and photodynamic priming of platinum‐resistant ovarian cancer cells under fluid shear stress
Over 75% percent of ovarian cancer patients are diagnosed with advanced‐stage disease characterized by unresectable intraperitoneal dissemination and the presence of ascites, or excessive fluid build‐up within the abdomen. Conventional treatments include cytoreductive surgery followed by multi‐line platinum and taxane chemotherapy regimens. Despite an initial response to treatment, over 75% of patients with advanced‐stage ovarian cancer will relapse and succumb to platinum‐resistant disease. Recent evidence suggests that fluid shear stress (FSS), which results from the movement of fluid such as ascites, induces epithelial‐to‐mesenchymal transition and confers resistance to carboplatin in ovarian cancer cells. This study demonstrates, for the first time, that FSS‐induced platinum resistance correlates with increased cellular protoporphyrin IX (PpIX), the penultimate downstream product of heme biosynthesis, the production of which can be enhanced using the clinically approved pro‐drug aminolevulinic acid (ALA). These data suggest that, with further investigation, PpIX could serve as a fluorescence‐based biomarker of FSS‐induced platinum resistance. Additionally, this study investigates the efficacy of PpIX‐enabled photodynamic therapy (PDT) and the secretion of extracellular vesicles under static and FSS conditions in Caov‐3 and NIH:OVCAR‐3 cells, two representative cell lines for high‐grade serous ovarian carcinoma (HGSOC), the most lethal form of the disease. FSS induces resistance to ALA‐PpIX‐mediated PDT, along with a significant increase in the number of EVs. Finally, the ability of PpIX‐mediated photodynamic priming (PDP) to enhance carboplatin efficacy under FSS conditions is quantified. These preliminary findings in monolayer cultures necessitate additional studies to determine the feasibility of PpIX as a fluorescence‐based indicator, and mediator of PDP, to target chemoresistance in the context of FSS.
- 27 August 2024
- Published by Wiley in Photochemistry and Photobiology
- Vol. 100 (6) , 1603-1621
Open AccessPpIX‐enabled fluorescence‐based detection and photodynamic priming of platinum‐resistant ovarian cancer cells under fluid shear stress
Over 75% percent of ovarian cancer patients are diagnosed with advanced‐stage disease characterized by unresectable intraperitoneal dissemination and the presence of ascites, or excessive fluid build‐up within the abdomen. Conventional treatments include cytoreductive surgery followed by multi‐line platinum and taxane chemotherapy regimens. Despite an initial response to treatment, over 75% of patients with advanced‐stage ovarian cancer will relapse and succumb to platinum‐resistant disease. Recent evidence suggests that fluid shear stress (FSS), which results from the movement of fluid such as ascites, induces epithelial‐to‐mesenchymal transition and confers resistance to carboplatin in ovarian cancer cells. This study demonstrates, for the first time, that FSS‐induced platinum resistance correlates with increased cellular protoporphyrin IX (PpIX), the penultimate downstream product of heme biosynthesis, the production of which can be enhanced using the clinically approved pro‐drug aminolevulinic acid (ALA). These data suggest that, with further investigation, PpIX could serve as a fluorescence‐based biomarker of FSS‐induced platinum resistance. Additionally, this study investigates the efficacy of PpIX‐enabled photodynamic therapy (PDT) and the secretion of extracellular vesicles under static and FSS conditions in Caov‐3 and NIH:OVCAR‐3 cells, two representative cell lines for high‐grade serous ovarian carcinoma (HGSOC), the most lethal form of the disease. FSS induces resistance to ALA‐PpIX‐mediated PDT, along with a significant increase in the number of EVs. Finally, the ability of PpIX‐mediated photodynamic priming (PDP) to enhance carboplatin efficacy under FSS conditions is quantified. These preliminary findings in monolayer cultures necessitate additional studies to determine the feasibility of PpIX as a fluorescence‐based indicator, and mediator of PDP, to target chemoresistance in the context of FSS.
- Open Access
- 27 August 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 1978-1987
5-Aminolevulinic acid-mediated photodynamic therapy in combination with kinase inhibitor lapatinib enhances glioblastoma cell death
5-Aminolevulinic acid (ALA) is an intraoperative imaging agent approved for protoporphyrin IX (PpIX) fluorescence-guided resection of glioblastoma (GBM). It is currently under clinical evaluation for photodynamic therapy (PDT) after the completion of GBM surgery. We previously showed that lapatinib, a clinical kinase inhibitor of epidermal growth factor receptor 1 & 2 (EGFR and HER2), enhanced PpIX fluorescence in a panel of GBM cell lines by blocking ABCG2 (ATP-binding cassette super-family G member 2)-mediated PpIX efflux, which suggests its potential for improving ALA for GBM surgery and PDT. Here we show that lapatinib enhanced PDT-induced cytotoxicity by promoting GBM cell death with the induction of apoptosis followed by necrosis. While the induction of tumor cell apoptosis was massive and rapid in the H4 cell line with no detectable Bcl-2 and a low level of Bcl-xL, it was delayed and much less in extent in A172, U-87 and U-118 cell lines with higher levels of pro-survival Bcl-2 family proteins. Lapatinib treatment alone neither reduced GBM cell viability nor had any significant effect on EGFR downstream signaling. Its enhancement of ALA–PDT was largely due to the increase of intracellular PpIX particularly in the mitochondria, resulting in the activation of mitochondria-mediated apoptosis in H4 cells. Our present study demonstrates that lapatinib inhibits ABCG2-mediated PpIX efflux and sensitizes GBM cells to ALA–PDT by inducing tumor cell death.
- 27 August 2024
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 1978-1987
Open Access5-Aminolevulinic acid-mediated photodynamic therapy in combination with kinase inhibitor lapatinib enhances glioblastoma cell death
5-Aminolevulinic acid (ALA) is an intraoperative imaging agent approved for protoporphyrin IX (PpIX) fluorescence-guided resection of glioblastoma (GBM). It is currently under clinical evaluation for photodynamic therapy (PDT) after the completion of GBM surgery. We previously showed that lapatinib, a clinical kinase inhibitor of epidermal growth factor receptor 1 & 2 (EGFR and HER2), enhanced PpIX fluorescence in a panel of GBM cell lines by blocking ABCG2 (ATP-binding cassette super-family G member 2)-mediated PpIX efflux, which suggests its potential for improving ALA for GBM surgery and PDT. Here we show that lapatinib enhanced PDT-induced cytotoxicity by promoting GBM cell death with the induction of apoptosis followed by necrosis. While the induction of tumor cell apoptosis was massive and rapid in the H4 cell line with no detectable Bcl-2 and a low level of Bcl-xL, it was delayed and much less in extent in A172, U-87 and U-118 cell lines with higher levels of pro-survival Bcl-2 family proteins. Lapatinib treatment alone neither reduced GBM cell viability nor had any significant effect on EGFR downstream signaling. Its enhancement of ALA–PDT was largely due to the increase of intracellular PpIX particularly in the mitochondria, resulting in the activation of mitochondria-mediated apoptosis in H4 cells. Our present study demonstrates that lapatinib inhibits ABCG2-mediated PpIX efflux and sensitizes GBM cells to ALA–PDT by inducing tumor cell death.
- 13 March 2024
- Published by Wiley in Photochemistry and Photobiology
- Vol. 100 (6) , 1579-1589
Effectiveness of lapatinib for enhancing 5‐aminolevulinic acid‐mediated protoporphyrin IX fluorescence and photodynamic therapy in human cancer cell lines with varied ABCG2 activities
5‐Aminolevulinic acid (ALA) is a prodrug for protoporphyrin IX (PpIX)‐mediated photodynamic therapy (PDT) and fluorescence‐guided tumor surgery. We previously reported that lapatinib, a repurposed ABCG2 inhibitor, enhanced ALA‐induced PpIX fluorescence and PDT by blocking ABCG2‐mediated PpIX efflux. In the present study, we evaluated how the variation in ABCG2 activities/protein levels affected tumor cell response to the enhancement of PpIX/PDT by lapatinib and Ko143, an ABCG2 tool inhibitor. ABCG2 activities and protein levels were determined in a panel of human cancer cell lines. Effects of lapatinib and Ko143 on enhancing ALA‐PpIX fluorescence and PDT were evaluated and correlated with tumor cell ABCG2 activities. We found that both lapatinib and Ko143 enhanced ALA‐PpIX fluorescence and PDT in a dose‐dependent manner, although lapatinib exhibited lower efficacy and potency than Ko143 in nearly all cancer cell lines. The EC50 of ABCG2 inhibitors for enhancing ALA‐PpIX and PDT had a positive correlation with tumor cell ABCG2 activities, indicating that tumor cell lines with lower ABCG2 activities were more sensitive to ABCG2 inhibitors for PpIX/PDT enhancement. Our results suggest that, for optimal therapeutic enhancement, the dose of ABCG2 inhibitors needs to be tailored based on the ABCG2 expression/activity in tumors.
- 13 March 2024
- Published by Wiley in Photochemistry and Photobiology
- Vol. 100 (6) , 1579-1589
Effectiveness of lapatinib for enhancing 5‐aminolevulinic acid‐mediated protoporphyrin IX fluorescence and photodynamic therapy in human cancer cell lines with varied ABCG2 activities
5‐Aminolevulinic acid (ALA) is a prodrug for protoporphyrin IX (PpIX)‐mediated photodynamic therapy (PDT) and fluorescence‐guided tumor surgery. We previously reported that lapatinib, a repurposed ABCG2 inhibitor, enhanced ALA‐induced PpIX fluorescence and PDT by blocking ABCG2‐mediated PpIX efflux. In the present study, we evaluated how the variation in ABCG2 activities/protein levels affected tumor cell response to the enhancement of PpIX/PDT by lapatinib and Ko143, an ABCG2 tool inhibitor. ABCG2 activities and protein levels were determined in a panel of human cancer cell lines. Effects of lapatinib and Ko143 on enhancing ALA‐PpIX fluorescence and PDT were evaluated and correlated with tumor cell ABCG2 activities. We found that both lapatinib and Ko143 enhanced ALA‐PpIX fluorescence and PDT in a dose‐dependent manner, although lapatinib exhibited lower efficacy and potency than Ko143 in nearly all cancer cell lines. The EC50 of ABCG2 inhibitors for enhancing ALA‐PpIX and PDT had a positive correlation with tumor cell ABCG2 activities, indicating that tumor cell lines with lower ABCG2 activities were more sensitive to ABCG2 inhibitors for PpIX/PDT enhancement. Our results suggest that, for optimal therapeutic enhancement, the dose of ABCG2 inhibitors needs to be tailored based on the ABCG2 expression/activity in tumors.
- 17 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115851
Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy
- 17 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115851
Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy
- Open Access
- 21 April 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (4) , 496
5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy
5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.
- 21 April 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (4) , 496
Open Access5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy
5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.
- 1 August 2022
- Published by Wiley in Photochemistry and Photobiology
- Vol. 99 (2) , 787-792
Analysis of Renal Cell Carcinoma Cell Response to the Enhancement of 5‐aminolevulinic Acid‐mediated Protoporphyrin IX Fluorescence by Iron Chelator Deferoxamine†
As a tumor photodiagnostic agent, 5‐aminolevulinic acid (ALA) is metabolized in the heme biosynthesis pathway to produce protoporphyrin IX (PpIX) with fluorescence. ALA‐PpIX fluorescence was evaluated in human renal cell carcinoma (RCC) cell lines and non‐tumor HK‐2 cell lines. We found that extracellular PpIX level was correlated with ABCG2 activity, illustrating its importance as a PpIX efflux transporter. Extracellular PpIX was also related to the Km of ferrochelatase (FECH) that chelates PpIX with ferrous iron to form heme. The Vmax of FECH was higher in all RCC cell lines tested than in the HK‐2 cell line. TCGA dataset analysis indicates a positive correlation between FECH expression and RCC patient survival. These findings suggest FECH as an important biomarker in RCC. Effects of iron chelator deferoxamine (DFO) on the enhancement of PpIX fluorescence were assessed. DFO increased intracellular PpIX in both tumor and non‐tumor cells, resulting in no gain in tumor/non‐tumor fluorescence ratios. DFO appeared to increase ALA‐PpIX more at 1‐h than at 4‐h treatment. There was an inverse correlation between ALA‐PpIX fluorescence and the enhancement effect of DFO. These results suggest that enhancement of ALA‐PpIX by DFO may be limited by the availability of ferrous iron in mitochondria following ALA administration.
- 1 August 2022
- Published by Wiley in Photochemistry and Photobiology
- Vol. 99 (2) , 787-792
Analysis of Renal Cell Carcinoma Cell Response to the Enhancement of 5‐aminolevulinic Acid‐mediated Protoporphyrin IX Fluorescence by Iron Chelator Deferoxamine†
As a tumor photodiagnostic agent, 5‐aminolevulinic acid (ALA) is metabolized in the heme biosynthesis pathway to produce protoporphyrin IX (PpIX) with fluorescence. ALA‐PpIX fluorescence was evaluated in human renal cell carcinoma (RCC) cell lines and non‐tumor HK‐2 cell lines. We found that extracellular PpIX level was correlated with ABCG2 activity, illustrating its importance as a PpIX efflux transporter. Extracellular PpIX was also related to the Km of ferrochelatase (FECH) that chelates PpIX with ferrous iron to form heme. The Vmax of FECH was higher in all RCC cell lines tested than in the HK‐2 cell line. TCGA dataset analysis indicates a positive correlation between FECH expression and RCC patient survival. These findings suggest FECH as an important biomarker in RCC. Effects of iron chelator deferoxamine (DFO) on the enhancement of PpIX fluorescence were assessed. DFO increased intracellular PpIX in both tumor and non‐tumor cells, resulting in no gain in tumor/non‐tumor fluorescence ratios. DFO appeared to increase ALA‐PpIX more at 1‐h than at 4‐h treatment. There was an inverse correlation between ALA‐PpIX fluorescence and the enhancement effect of DFO. These results suggest that enhancement of ALA‐PpIX by DFO may be limited by the availability of ferrous iron in mitochondria following ALA administration.